Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00191516
Status:
COMPLETED
Last Update Posted:
2007-01-26
First Post:
2005-09-12
Brief Title:
An Open-Label Study of Atomoxetine in Children With Attention-DeficitHyperactivity Disorder
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
An Open-Label Study on Effectiveness and Tolerability of Atomoxetine as Perceived by Patients Parents and Physicians in Children With Attention-DeficitHyperactivity Disorder in Germany
Status:
COMPLETED
Status Verified Date:
2007-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A single arm open-label phase 3 multicenter study to evaluate the effectiveness and tolerability of atomoxetine given once daily target dose 12 mgkgday as perceived by patients parents and physicians and its impact on quality of sleep in children aged 6 through 11 years with Attention-DeficitHyperactivity Disorder treated as outpatients in Germany An 8-week treatment phase is followed by a 16-week extension period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| B4Z-SB-LYDD | None | None | None |